Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19731218 | 0.87 | EPHX2 (0.35) | ALDH1A1HTTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6079513 | 0.78 | GPR84 (0.31) | — | |
| SCHEMBL13498451 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HTTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL31443083 | 0.76 | ALDH1A1 (0.47) | ALDH1A1HTTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL228021 | 0.74 | — | — | |
| SCHEMBL3061834 | 0.72 | — | — | |
| SCHEMBL228277 | 0.71 | ALDH1A1 (0.43) | ALDH1A1HTTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL782534 | 0.70 | — | — | |
| SCHEMBL944433 | 0.69 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL18659965 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | ALDH1A1 903/4885HTT 4802/4885RAB9A 4434/4885 |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR5, CCR3 | ALDH1A1 1547/4885HTT 4782/4885RAB9A 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.